CCO Oncology Podcast

189 Episodes

1. Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

   Published: 3/25/2025
2. Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

   Published: 2/20/2025
3. Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

   Published: 2/10/2025
4. Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

   Published: 1/9/2025
5. Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

   Published: 10/22/2024
6. Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

   Published: 10/16/2024
7. ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

   Published: 10/1/2024
8. A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

   Published: 9/30/2024
9. Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

   Published: 9/6/2024
10. Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

    Published: 9/5/2024
11. ROS1-Alterations and Molecular Testing in Advanced NSCLC

    Published: 8/28/2024
12. Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

    Published: 8/5/2024
13. Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

    Published: 7/22/2024
14. Current Clinical Practice and NCCN Guidelines for CLL/SLL

    Published: 7/18/2024
15. Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

    Published: 7/12/2024
16. CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

    Published: 7/11/2024
17. Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

    Published: 7/9/2024
18. Congress to Clinic: Expert Takeaways on Emerging Data for AML

    Published: 7/8/2024
19. Congress to Clinic: Expert Takeaways on Emerging Data for MDS

    Published: 7/5/2024
20. Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

    Published: 5/14/2024